Rhenman & Partners Asset Management’s Immunocore IMCR Stock Holding History

Rhenman & Partners Asset Management’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.58M	Sell	85,724 -67,554	-44%	-$2.19M	0.32%	75
2025 Q4	$5.32M	Buy	153,278 +125,000	+442%	+$4.41M	0.5%	62
2025 Q3	$1.03M	Hold	28,278	–	–	0.11%	90
2025 Q2	$887K	Hold	28,278	–	–	0.11%	88
2025 Q1	$839K	Sell	28,278 -30,000	-51%	-$900K	0.1%	88
2024 Q4	$1.72M	Hold	58,278	–	–	0.18%	83
2024 Q3	$1.81M	Hold	58,278	–	–	0.15%	87
2024 Q2	$1.98M	Sell	58,278 -21,500	-27%	-$1.1M	0.19%	77
2024 Q1	$5.19M	Sell	79,778 -4,500	-5%	-$309K	0.49%	53
2023 Q4	$5.76M	Sell	84,278 -5,000	-6%	-$260K	0.58%	56
2023 Q3	$4.63M	Hold	89,278	–	–	0.5%	51
2023 Q2	$5.35M	Sell	89,278 -42,010	-32%	-$2.4M	0.56%	55
2023 Q1	$6.24M	Sell	131,288 -18,712	-12%	-$1.05M	0.68%	49
2022 Q4	$8.56M	Hold	150,000	–	–	0.89%	41
2022 Q3	$8.57M	Buy	150,000 +10,000	+7%	+$477K	0.9%	44
2022 Q2	$5.22M	Sell	140,000 -30,472	-18%	-$990K	0.59%	52
2022 Q1	$5.1M	Buy	170,472 +80,472	+89%	+$2.03M	0.5%	61
2021 Q4	$3.07M	Hold	90,000	–	–	0.2%	83
2021 Q3	$3.34M	Hold	90,000	–	–	0.23%	84
2021 Q2	$3.52M	Buy	+90,000	New	+$3.47M	0.24%	85

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Rhenman & Partners Asset Management's IMCR Position: Q1 2026 in Review

Rhenman & Partners Asset Management reduced its Immunocore (IMCR) stake by 44% in Q1 2026, selling an estimated $2.19M and leaving 85,724 shares worth $2.58M. The position accounts for 0.32% of the portfolio, ranked #75.

Rhenman & Partners Asset Management first reported a position in IMCR in Q2 2021 and has held it in 20 quarters since. The position peaked at $8.57M in Q3 2022. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

Rhenman & Partners Asset Management held 85,724 shares of Immunocore worth $2.58M as of Q1 2026.
Rhenman & Partners Asset Management sold 67,554 Immunocore shares in Q1 2026, an estimated $2.19M.
Immunocore made up 0.32% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #75 holding.
Rhenman & Partners Asset Management first reported a position in Immunocore in Q2 2021 and has held it in 20 quarters since.
Rhenman & Partners Asset Management's Immunocore position peaked at $8.57M in Q3 2022.
142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.